Tianfeng Securities released a research report on April 23 stating that it gave Dirui Healthcare (300396.SZ) a purchase rating. The main reasons for the rating include: 1) strengthening channel empowerment, which is worth looking forward to; 2) continuing to increase overseas, major customer strategy+localization management upgrades drive high growth in the international market; 3) changes in product structure are expected to drive increased profitability. (Mainichi Keizai Shimbun)
天风证券4月23日发布研报称，给予迪瑞医疗（300396.SZ）买入评级。评级理由主要包括：1）加强渠道赋能，试剂上量值得期待；2）持续加码海外，大客户策略+本地化管理升级带动国际市场高增；3）产品结构变化有望带动盈利能力提升。（每日经济新闻）
Tianfeng Securities released a research report on April 23 stating that it gave Dirui Healthcare (300396.SZ) a purchase rating. The main reasons for the rating include: 1) strengthening channel empowerment, which is worth looking forward to; 2) continuing
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.